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ABSTRACT. Rubinstein-Taybi syndrome is a rare autosomal dominant 
congenital disorder characterized by postnatal growth retardation, 
psychomotor developmental delay, skeletal anomalies, peculiar facial 
morphology, and tumorigenesis. Mutations in the gene encoding the 
cAMP response element-binding (CREB) protein on chromosome 
16p13.3 have been identified. In addition, some patients with low 
intelligence quotients and autistic features bear large deletions. Based 
on these observations, we used multiplex ligation-dependent probe 
amplification to search for large deletions affecting CREB protein 
gene in a Rubinstein-Taybi Syndrome patient. We identified a novel 
heterozygote deletion removing five exons (exons 17-21), encoding 
the histone acetyltransferase domain. We propose the use of multiplex 
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ligation-dependent probe amplification as a fast, accurate and cheap test 
for detecting large deletions in the CREB protein gene in the sub-group 
of Rubinstein-Taybi syndrome patients with low intelligence quotients 
and autistic features.
Key words: Comparative multiplex dosage analysis (CMDA); 
CREB-binding protein (CREBBP); Rubinstein-Taybi Syndrome (RTS); 
Multiplex ligation-dependent probe amplification (MLPA)
INTRODUCTION
Rubinstein-Taybi Syndrome (RTS) [Mendelian Inheritance in Man (MIM) 
#180849] is an autosomal dominant disease occurring in 1 out of 125,000 births (Hen-
nekam et al., 1990; Wiley et al., 2003) that is characterized by growth retardation, psy-
chomotor development delay, broad and/or bifid distal phalanges of thumbs and halluces, 
atypical facial morphology, short stature, and moderate to severe intellectual disability 
(ID). Other features include coloboma, cardiac anomalies, keloid formation in scars, and 
increased risk of tumor formation (Bartsch et al., 2006). RTS results from de novo het-
erozygous point mutations or deletions of the cAMP response element-binding (CREB)-
binding protein (CREBBP; Petrij et al., 1995) and E1A-associated protein p300 (EP300) 
(Bartsch et al., 2010) genes. Individuals reported with mutations in EP300 have a milder 
skeletal phenotype, lacking typical broadening and angulation of the thumb and hallux 
(Bartholdi et al., 2007).
The CREBBP gene includes 31 exons, spans approximately 155 kb of genomic DNA 
and is located on chromosome 16p13.3. EP300 also contains 31 exons, spans approximate-
ly 87 kb of genomic DNA and is located on chromosome 22q13.2. CREB-binding protein 
(CBP) is a transcriptional co-activator that has intrinsic histone acetyltransferase (HAT) ac-
tivity and is involved in various signal transduction pathways that regulate the expression cell 
growth, differentiation, DNA repair, apoptosis, and tumor suppression (Chrivia et al., 1993; 
Giles et al., 1998).
Several molecular techniques, such as fluorescence in situ hybridization (FISH; 
McGaughran et al., 1996), denaturing high-performance liquid chromatography (Udaka 
et al., 2006), array comparative gene hybridization (CGH; Gervasini et al., 2010), DNA 
sequencing (Bentivegna et al., 2006), and real-time PCR (Coupry et al., 2004) have been 
used to identify mutations in the CREBBP gene. In this study, we report the identification of 
a novel mutation in the CREBBP gene and demonstrate that multiplex ligation-dependent 
probe amplification (MLPA) is a reliable and efficient method for detecting large deletions 
of the CREBBP gene in the subgroup of RTS patients with lower Intelligence Quotient (IQ) 
and autistic features.
MATERIAL AND METHODS
Case report
The patient is the 3-year-old daughter of unrelated parents. Her family history shows 
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only a maternal uncle with ID, epilepsy, and an autistic disorder. She was born by Cesarean 
section for fetal distress after a pregnancy characterized by decreased fetal growth. The 
perinatal history was characterized by asphyxia, which was quickly resolved. Psychomotor 
development milestones have been reached with delay (sitting alone at 12 months), and she 
currently only speaks the words “mom” and “dad”, walks with support, and has not achieved 
sphincter control. Her personal history shows failure to thrive, and she is currently slightly 
below the 3rd centile for weight and height, with OFC -4SD. Facial morphology shows 
columella protruding below alae nasi with a thin beaked nose, short philtrum, hypertelorism 
with down-slanting palpebral fissures and a thin upper lip. A small pink nodular lesion, with 
a hard/elastic consistence and the size of a pea, was detectable over the posterior surface of 
the left ear. The lesion was completely removed and its histological examination allowed us 
to make the diagnosis of spontaneous keloid. She shows broad thumbs and the halluces are 
both broad and bifid on the left. She scores 12 months of mental age on the Griffiths mental 
development scale, corresponding to moderate mental retardation. Informed consent was 
obtained from the patient’s parents prior to the present study.
MLPA analysis
Genomic DNA was isolated from peripheral blood lymphocytes using the salt 
chloroform extraction method. Quantification of DNA extracted from each sample was 
performed using the Nanodrop ND-1000 spectrophotometer (Thermo Scientific, Waltham, 
MA, USA). DNA in solution was quantified and checked for degradation on an agarose 
gel. MLPA analysis was performed using the SALSA MLPA kit P313-A1 PAH (MRC-
Holland, Amsterdam, The Netherlands) as previously described by Schouten et al. (2002). 
The P313-A1 CREBBP probe mix contains probes for each of the 31 exons of the CREBBP 
gene (2 probes for exons 1, 2, and 3). In addition, it contains 3 probes for EP300 (exons 
1, 4, and 12). PCR products were identified and quantified by capillary electrophoresis on 
an ABI 3130 genetic analyzer, using the Gene Mapper software from Applied Biosystems 
(Foster City, CA, USA). In order to efficiently process the MLPA deletion/duplication 
data, a spreadsheet was generated in Microsoft Excel (Microsoft, Redmond, WA, USA). 
First, the data corresponding to each sample (patient and control DNAs) were normalized 
by dividing each probe’s signal strength (i.e., the area of each peak) by the average signal 
strength yielded by the 10 control probes to generate a relative peak area (RPA) value for 
each peak. The RPA value for each probe in the patient’s sample was then compared to 
that of the control sample by dividing, for each peak, the patient RPA by the control RPA. 
The latter ratio was then used to define the following categories: i) ~ 1 for the non-deleted/
non-duplicated gene region, ii) ~ 0.5 if deleted, and iii) ~ 1.5 if duplicated. Other details 
regarding the normalizing method and quality test have been described previously by Calì 
et al. (2010).
Comparative multiplex dosage analysis (CMDA)
CMDA was performed as previously described by Gable et al. (2003) and Calì et 
al. (2010) to confirm the deletion of the exons 17-21 of the CREBBP gene identified by 
MLPA. Briefly, only exons 16 and 22 (expected normal dosage) and 17 and 21 (expected 
©FUNPEC-RP www.funpecrp.com.brGenetics and Molecular Research (2013) Ahead of Print
F. Calì et al.
heterozygous deletion) of the CREBBP gene were co-amplified in a fluorescent multi-
plex PCR with myelin protein zero (PROZ), mutL homolog 1 (MLH1), and neuroligin 3 
(NLGN3) as control genes. A total of 10-15 pmol of each primer (sequencing and PCR 
conditions are available from the authors upon request) and 18 PCR cycles were used to 
ensure the reaction was kept within the exponential phase. The PCR products were re-
solved on an ABI3130 sequence analyzer (Applied Biosystems) according to manufacturer 
instructions. Results from the patient’s DNA (RSTS01A) were compared separately with 
those from 4 (2 males and 2 females) non-deleted, non-duplicated control individuals. The 
RPAs for each test were calculated as described above for the MLPA. The sensitivity of 
this test to detect deletion/duplication was also verified by comparing the RPAs between 
males (RPA ~ 0.5) and females (RPA ~ 1) using the X-linked NLGN3 gene as control. The 
results of RPA were segregated into the following categories: i) ~ 1, for the non-deleted/
non-duplicated gene region tested in the patient, ii) ~ 0.5 if deleted, and iii) ~ 1.5 if du-
plicated.
RESULTS AND DISCUSSION
RTS underlies a wide spectrum of molecular defects affecting the expression of the 
CREBBP gene, including frameshift, nonsense, splice site, missense mutations, and (less 
frequently) large deletions. Facial and thumb features are associated with all mutations. 
Growth retardation in height and weight has been observed more frequently in patients with-
out CREBBP mutations; seizures were more frequent in those with CREBBP mutations. The 
degree of ID is similar in all groups, although there is a trend toward lower IQ and autistic 
features in patients with large deletions (Schorry et al., 2008). These latter features led us 
to search for large deletions in our patient, although CREBBP gene deletions account only 
for approximately 10% of RTS patients (Petrij et al., 2000). Traditionally, FISH analysis has 
been employed to detect full gene deletions in the CREBBP gene (McGaughran et al., 1996; 
Bartsch et al., 1999). However, both FISH and commonly available array CGH analyses 
have limitations for the detection of small deletions. In these cases, MLPA is a suitable alter-
native. Moreover, MLPA can detect gene deletions in heterozygotes whereas DNA sequenc-
ing would fail due to the masking effect of the non-deleted allele (Calì et al., 2010). Based 
on the above considerations, we genotyped patient RSTS01A by MLPA instead of DNA 
sequencing, using the P313-A1 CREBBP kit (MRC-Holland), containing probes for all 31 
exons of the CREBBP gene. Patient RSTS01A showed an altered amplification pattern, 
compatible with a heterozygous novel deletion of exons 17-21 of the CREBBP gene (Figure 
1). This mutation was absent in parental samples, suggesting that the deletion occurred as a 
de novo event in one of the parents during gametogenesis. To confirm the preliminary MLPA 
finding, we developed an alternative semi-quantitative CMDA dosage, which confirmed this 
deletion (see Figure 2). This deletion involves the HAT domain, containing 44.7% of the 
exon variants, consistent with previous studies (Sharma et al., 2010). These findings con-
firmed the clinical diagnosis of RTS in the patient.
In conclusion, we propose MLPA as an inexpensive, fast, and accurate test for the 
initial screening for CREBBP gene deletions/duplications in all RTS patients displaying 
lower IQ and autistic features.
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Figure 1. Multiplex ligation-dependent probe amplification (MLPA) analysis of the CREBBP gene performed 
with the SALSA MLPA KIT P313-A1 in patient (RSTS01A) with Rubinstein-Taybi Syndrome. In this patient the 
MLPA revealed the deletion of exons 17, 18, 19, 20, 21. A. The electropherograms show results referring to probes 
obtained for i) patient (RSTS01A), ii) a negative control (“Control”). The asterisks above peaks indicate the deleted 
exons; B. graph displaying the ratios between the patient’s and control’s Relative Peak Areas (RPA) determined in 
the 16p13.3 region. Reference values are as follows: RPA ratio ~1 = normal dosage; RPA ratio ~0.5 = heterozygous 
deletion. See text for more details.
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Figure 2. Comparative multiplex dosage analysis (CMDA) analysis performed on patient RSTS01A bearing a 
deletion of the CREBBP gene removing exons 17-21. A. In the electropherogram, the asterisks above the peaks 
indicates the deleted exons 17 and 21 borne only by the patient but not by her parents (de novo mutation). Ex 16, 
17, 21, 22 refers to exons of CREBBP gene. B. Graph displaying the ratios between the RSTS01A patient’s and 
controls’ Relative Peak Areas (RPA) determined for the exons 16, 17, 21, 22 of the CREBBP gene (see text for 
explanation). Reference values are as follows: RPA ratio ~1 = normal dosage; RPA ratio ~0.5 = heterozygous 
deletion. MLH1, PROZ and NLGN3 are control probes used in the CMDA.
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